Carlo Marra

Research Scientist of Pharmacoepidemiology, BSc (Pharm), PharmD PhD

 

Appointments

  • Pro-Vice Chancellor, Faculty of Health Sciences, Curtin University

 

Research Interests

  • Health economics
  • Quality of life research
  • Pharmacoepidemiology

 

Professor Carlo Marra joined Curtin University as the Pro-Vice Chancellor of the Faculty of Health Sciences.  Previously he was the Dean of the School of Pharmacy at the University of Otago and Memorial University; before that, he was a Professor and the Director of CORE at the University of British Columbia.  He has extensive experience in academic leadership, research, health workforce development and health care and government – particularly in the areas of arthritis, and health care resource allocation to achieve optimal health outcomes.

Learn more

Carlo holds a Bachelor of Science (Pharmacy), a Doctor of Pharmacy, and a Doctor of Philosophy in Health Care and Epidemiology from the University of British Columbia, and has completed a post-doctoral fellowship at the Arthritis Research Centre of Canada in Arthritis Epidemiology and Pharmacoepidemiology. He has previously held a Canada Research Chair (CRC) in Pharmaceutical Outcomes and was a Michael Smith Foundation for Health Research Scholar at the University of British Columbia. Carlo also worked as a pharmacy clinician in the hospital environment, in primary care and in a rheumatology clinic.

Professor Marra is an internationally recognised scholar and has published widely on health economics and outcomes, efficient use of the health work force and pharmacoepidemiology. He has been published in almost 300 peer-reviewed articles and has received over $10d million in competitive research funding.

Publications

  1. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, Clarke AE, Gignac MA, Anis AH. Not all “quality-adjusted life years” are equal. Journal of Clinical Epidemiology (in press March 2007).
  2. Ayas NT, Fitzgerald JM, White DP, Schulzer M, Fleetham J, Cooper, Marra CA. The cost-effectiveness of continuous positive airway pressure therapy for obstructive sleep apnea hypopnea. Archives of Internal Medicine. 2006 May 8;166:977-84.
  3. Marra CA, Woolcott JC, Shojania K, Offer R, Kopec J, Brazier JE, Esdaile JM, Anis AH An assessment of the construct validity of four indirect utility measures in rheumatoid arthritis. Social Science and Medicine 2005;60(7):1571-82.
  4. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase (TPMT) polymorphisms in patients with rheumatological conditions treated with azathioprine. Journal of Rheumatology 2002;29:2507-12. Abstracted by the 2004 Year Book of Rheumatology (published by Mosby-Year Book, Inc.)
  5. Marra F, Lynd LD, Coombes M, Richardson K, Legal M, Fitzgerald JM, Marra CA.  Does antibiotic exposure during infancy lead to development of asthma? A systematic review and meta-analysis. Chest 2006;129:610-18.